PharmAla Biotech Holdings Inc. (CSE: MDMA) (OTC: MDXXF) has announced it will supply its GMP-grade LaNeo™ MDMA to a clinical trial at Mt. Sinai Health…
October 21, 2024
IceCure Wins U.S. Patent for Next-Generation Cryoablation System; Stock Trading Up 10%
IceCure Medical Ltd. (Nasdaq: ICCM) has secured a Notice of Allowance from the U.S. Patent and Trademark Office for its innovative “Cryogenic System Connector.” This…
October 21, 2024
Breakthrough Preclinical Results: MIRA Pharmaceuticals’ Ketamir-2 Surpasses Leading Neuropathic Pain Treatments
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) reports that its novel oral ketamine analog, Ketamir-2, has outperformed FDA-approved neuropathic pain treatments Gabapentin and Pregabalin in a recent…
Immutep Limited (ASX: IMM; NASDAQ: IMMP), a clinical-stage biotechnology company focused on LAG-3 immunotherapies, announced that its first-in-human Phase I study of IMP761 has progressed…
August 30, 2024
PRISM Weight Loss Index Leader LEXX Soars 24% on Positive DehydraTECH-Processed Rybelsus® Study Results
Lexaria Bioscience Corp. (NASDAQ: LEXX), today’s standout in the PRISM Weight Loss Index, saw its shares surge 24% following the announcement of promising results from…
CEO Josh Riggs of the molecular diagnostics technology company, Oncocyte (OCX) was featured on the MedTech Guru’s latest podcast episode 247, “Take Advantage of the…
Shares in late-stage clinical drug platform company Annovis Bio (Nasdaq: ANVS) soared nearly 40% on Friday after the company announced new data from its Phase…
Biotechnology struggled in the public equity markets in 2023, hit by a combination of depressed investor sentiment, regulatory challenges, geopolitical tensions, and supply chain disruptions. …
Clinical-stage biopharmaceutical company, Altimmune, Inc (Nasdaq: ALT) topped the PRISM Global Health Index on Monday morning after the company presented data from a 48-week Phase…
Shares in biotechnology company, NKGen Biotech (Nasdaq: NKGN) soared more than 75% in morning trading on Monday after the company announced that its lead candidate…
Glioblastoma is a complex, aggressive brain cancer that has no cure. The median length of survival following diagnosis is between 15 and 18 months, and…
Leading regenerative medicine company, BioStem Technologies (OTC: BSEM) has reported record revenues for the fourth quarter of 2023, reaching $11.5 million, a 1,355% increase year-over-year….